The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.


Hepatitis C Treatment for Drug Users

Back to News Homepage


Oral Hep C Trio Cured Over 90 Percent in Phase II Trial

Scripps Finds Antibody that Could Prevent Hep C

April 9, 2012

Print this page

Using an approach called exhaustive panning, Scripps researchers have advanced the search for a Hepatitis C vaccine by identifying the antibody AR4A.

Promising Vaccine Targets On Hepatitis C Virus

ScienceDaily (Apr. 3, 2012) — A team led by scientists at The Scripps Research Institute has found antibodies that can prevent infection from widely differing strains of hepatitis C virus (HCV) in cell culture and animal models.

HCV’s very high rate of mutation normally helps it to evade its host’s immune system. The newly discovered antibodies, however, attach to sites on the viral envelope that seldom mutate. One of the new antibodies, AR4A, shows broader HCV neutralizing activity than any previously reported anti-HCV antibody.

“These antibodies attach to sites on the viral envelope that were previously unknown, but now represent promising targets for an HCV vaccine,” said Mansun Law, an assistant professor at Scripps Research. Law is the senior author of the new report, which appears online this week in the Proceedings of the National Academy of Sciences.

Continue reading this entire article:

Requirements for using and reposting articles